Biohaven (NYSE:BHVN) Stock, Quote.Headers.trade-ideas

Biohaven

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Biohaven Pharma Hldgs

Biohaven Pharmaceutical

YelpLogoAugust2021

News

Initiation

Markets

Analyst Ratings

Trading Ideas

BHVN

COYA

IMUX

YELP

This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday

wall street chart shutter2

Long Ideas

Insider Trades

Pre-Market Outlook

CSPI

PTWO

$1M Bet On Biohaven? Check Out These 3 Stocks Insiders Are Buying

Intraday Update

Movers

ALHC

AMSC

BIRK

BURL

BWLP

CRDO

FTEL

FWRD

INSM

RRGB

WOOF

HP Posts Upbeat Earnings, Joins Foot Locker, American Superconductor, Red Robin Gourmet Burgers And Other Big Stocks Moving Higher On Thursday

Biohaven Ltd

R1T, the first electric pickup to hit the road, was the showpiece that launched Rivian Automotive (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rivn#NASDAQ">RIVN</a>). But considering that the&nbsp;R1S SUV&nbsp;became the signature vehicle Rivian got known for, launching the world&rsquo;s first electric pickup wasn&rsquo;t enough to launch Rivian among the EV stars. Even Ford Motor (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/f#NYSE">F</a>) couldn&rsquo;t repeat its F-150 best-selling success on the EV front. Not to mention the EV king, Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>), who&nbsp;successfully launched the Cybertruck after quite a bit of delays, only to face a new set of challenges. Even Tesla ended up short on the electric pickup front, with Cybertruck sales being pale compared to Model Y and Model 3. To sum it up, SUVs won against pickups in the EV race. For now.
Putting it simply, a larger EV means a less efficient EV. To move around, a heavier vehicle needs more energy and therefore, huge batteries. Rivian somewhat solved this equation with R1T&nbsp;that has the range option of&nbsp;420 miles, but it requires a huge and expensive battery pack. Stellantis N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stla#NYSE">STLA</a>) is claiming its all-electric Ram 1500 REV pickup will outperform its competitors with range, towing, payload, and charging times.&nbsp;Scheduled to arrive to dealerships early next year, this will be Ram&rsquo;s first electric pickup.&nbsp;2025 1500 REV&nbsp;will come with two battery options, resulting in targeted ranges of&nbsp;350-miles and up to 500 miles.&nbsp;This means Stellantis will leave behind not only Rivian, but also the pickup king, Ford and its 2024 Lightning, whose extended range of 320 miles, and the EV king, Tesla, whose Cybetruck has en estimated driving range of 340 miles. However, it&rsquo;s no secret that Stellantis is also struggling, both in North America and in Europe, with Chinese EV makers setting up shop as they continue to expand their global footprint. But, despite challenges and weak results for the first half of the year, including a profit dive of 48%, Stellantis is not giving up. Earlier this month, it revealed its plans to invest $406 million to retool three Michigan plants for EV production. But also, it is slowing down as a week ago, it decided to pause the production of electric Fiat 500 model for four weeks, with the plant in Turin will undergo a significant transformation, involving an investment of &euro;100 million, being equipped for developing a hybrid version of the model. Therefore, Stellantis is yet to fulfill its electric pickup promise.&nbsp;
<h3>The Good News Is That All Electric Pickups Just Got Some Solar Power</h3>
Meanwhile, Worksport Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wksp#NASDAQ">WKSP</a>), an innovative maker of hybrid and clean energy solutions for light trucks and global consumer goods, just initiated the Alpha Launch of its solar-power duo that pickups can greatly benefit from. Its off-grid power on the go duo consists of SOLIS solar-powered tonneau cover and COR mobile battery power generator. Worksport is planning to bring this innovative system to market in three phases, beginning with the Alpha release, followed by the Beta release and ultimately, a full-scale market launch. The initial Alpha release of its cutting-edge nano-grid system has officially been initiated, with Worksport announcing that approximately 100 systems have been set for rigorous testing and public exposure.&nbsp;Worksport already revealed that the SOLIS will be available for major truck brands including Ford, General Motors Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gm#NYSE">GM</a>) and the Hyundai Motor Company (OTC: <a class="ticker" href="https://www.benzinga.com/stock/hymtf#OTC">HYMTF</a>). In addition, Worksport revealed earlier this month successful lab test results of the portable COR battery system as a range extender for Tesla, namely its Model 3 and Cybertruck.
Therefore, the above examples show that as technologies improve and economies of scale emerge, electric pickups will be in a much more favorable position in the future.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Penny Stocks

HYMTF

RIVN

STLA

TSLA

WKSP

Electric Pickups Just Got Some Solar Power To Ease Their Struggles

WIIM

Trump Media & Technology Group shares are trading lower, possibly amid the expiration of the lockup period that prevents large shareholders, such as Donald Trump, from selling stocks. Also, 2024 Presidential polls show that Donald Trump is behind rival candidate, Vice President Harris.

RBC Capital analyst Scott Hanold reiterates Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) with a Outperform and maintains $200 price target.

Price Target

Reiteration

CHRD

RBC Capital Reiterates Outperform on Chord Energy, Maintains $200 Price Target

Charles Hoskinson, co-founder of Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Cardano (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>), has voiced concerns over the new digital assets platform backed by former President Donald Trump and his sons.
What Happened: In an <a href="https://www.ft.com/content/7a497898-38b7-4e84-9e8a-c2469ebafdc1">interview</a> with the Financial Times on Friday, Hoskinson expressed reservations about the Trump-supported venture, <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40905315/donald-trumps-new-crypto-project-world-liberty-financial-everything-you-need-to-know">World Liberty Financial</a>. This decentralized finance (DeFi) platform aims to offer financial services without the need for intermediaries such as banks or exchanges.
The Cardano blockchain's founder fears this platform could become a political issue.
&#8220;Trump is launching a DeFi application, and that's scary to me as an industry,&#8221; Hoskinson said.
"Everything Trump does the left hates with such a passion," he stated. "He's taken a bipartisan thing and he's making it partisan." 
He further speculated that Democrats might "attempt to weaponize the institutions of the United States to slow down and damage Trump," potentially leading to investigations by the Department of Justice or the SEC.
Despite Trump's recent outreach to the crypto industry and support from influential crypto investors, Hoskinson doubts that either Trump or Kamala Harris, if elected, would foster a <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40934959/anthony-scaramucci-says-donald-trump-is-a-polarizing-person-but-pulling-democrats-along-on">robust cryptocurrency industry</a> in the U.S.
While in Singapore, Hoskinson lauded the city-state&#8217;s political neutrality and its potential to simplify and embrace decentralized identity, contrasting it with Hong Kong&#8217;s absorption into mainland China&#8217;s political system.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40919168/ethereum-co-founder-says-donald-trump-is-certainly-the-favorite-over-kamala-harris-for-cry">Ethereum Co-Founder Says Donald Trump Is &#8216;Certainly The Favorite&#8217; Over Kamala Harris For Crypto</a>
Why It Matters: The politicization of the crypto industry could lead to a polarized environment, potentially hindering its growth and development. 
Hoskinson&#8217;s concerns highlight the potential risks associated with political involvement in the crypto space. It remains to be seen how these developments will impact the future of the industry.
In a CNBC interview, Hoskinson <a href="https://x.com/StakeWithPride/status/1837000689412719025">highlighted</a> that the world is embracing cryptocurrencies with or without America and is trending towards decentralization.
He highlighted that many from the Trump camp are open to fair regulation and engagement dialogue which is in contrast to the Democratic Party. However, the younger-aged group is open to dialogue about the sense of regulation.
He added "Trump is Trump…he is an anomaly" and a convergence between the two parties should be <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40919168/ethereum-co-founder-says-donald-trump-is-certainly-the-favorite-over-kamala-harris-for-cry">good for crypto regulations</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40671893/ethereum-killer-ada-set-to-get-a-utility-boost-as-cardano-upgrade-chang-goes-live">&#8216;Ethereum Killer&#8217; ADA Set To Get A Utility Boost As Cardano Upgrade &#8216;Chang&#8217; Goes Live</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ADA

$ETH

Ethereum Co-Founder Says Donald Trump's DeFi Platform Is 'Scary' Because 'Everything Trump Does The Left Hates With Such A Passion'

Loop Capital analyst Chris Dankert maintains Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) with a Buy and lowers the price target from $160 to $130.

ATKR

Loop Capital Maintains Buy on Atkore, Lowers Price Target to $130

Guidance

Olo Reduces Workforce By ~9%; Estimates It Will Incur Charges Of ~$2.2M-$2.6M In Connection With Workforce Reduction, Which Is Expected To Be Incurred Q3

Loop Capital analyst Jeffrey Stevenson maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Buy and raises the price target from $190 to $230.

BLDR

Loop Capital Maintains Buy on Builders FirstSource, Raises Price Target to $230

APLS

Apellis Pharmaceuticals shares are trading lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency has confirmed its June 2024 negative opinion on the company's intravitreal pepcetacoplan for geographic atrophy secondary to age-related macular degeneration.

Cardinal Health To Acquire Integrated Oncology Network For $1.115B, Expanding Navista Alliance With Over 100 Providers Across 50 Community-Based Sites In 10 States

Editor&#8217;s Note: The article has been updated to reflect the correct company, Viking Holdings Ltd.
On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer recommended buying Viking Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>). &#8220;This is a really fine company, and it will do well for multiple years because they have many <a href="https://www.benzinga.com/quote/VKTX/news">ships coming in,&#8221; he added.</a>
On Sept. 11, JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65.
Gentex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTX#NASDAQ">GNTX</a>) is &#8220;too closely related to autos, and autos have been hurt so bad. And I don't see a quick turn. We're going to need several Fed rate cuts before they turn,&#8221; Cramer said.
On July 26, the company reported second-quarter earnings per share of 37 cents, but it missed the street view of 52 cents. Quarterly sales of $572.93 million missed the analyst consensus of $622.79 million.
The Mad Money host said Cadre Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDRE#NYSE">CDRE</a>) is a &#8220;good simple story.&#8221;
On Aug. 9, Cadre Hldgs reported quarterly earnings of 31 cents per share which beat the analyst consensus estimate of 27 cents per share. The company reported quarterly sales of $144.31 million which beat the analyst consensus estimate of $142.05 million.
&#8220;Something's the matter with Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>),&#8221; Cramer said. &#8220;I want to know what's wrong.&#8221;
On Sept. 19, Celsius Holdings appointed Hans Melotte to the company&#8217;s Board of Directors.
Price Action:
<ul>
<li>Viking shares gained 5.8% to settle at $68.16 on Thursday.</li>
<li>Gentex shares gained 1.8% to close at $29.82 during the session.</li>
<li>Cadre shares gained 2.4% to close at $37.36 during Thursday's session.</li>
<li>Celsius shares fell 0.6% to settle at $34.07 on Thursday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40948972/coinbase-global-electronic-arts-and-2-other-stocks-executives-are-selling">Coinbase Global, Electronic Arts And 2 Other Stocks Executives Are Selling</a></li>
</ul>

Media

CDRE

CELH

GNTX

Jim Cramer: Viking Therapeutics Has 'Many Ships Coming In' (CORRECTED)

Friday, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS).
The <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-20-09-30-00-2949552" rel="noreferrer noopener">data</a> demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.69; p=0.0026).
Further analysis of secondary endpoints demonstrated that the number of participants who experienced confirmed disability improvement increased by nearly two-fold, 10% with tolebrutinib compared to 5% with placebo (HR 1.88; nominal p=0.021).
Based on the preliminary analysis of the HERCULES study, there was a slight increase in tolebrutinib-treated patients of some adverse events.
Liver enzyme elevations were observed in 4.1% of participants receiving tolebrutinib compared with 1.6% in the placebo group, a side effect also reported with other BTK inhibitors in MS.
All but one case of liver enzyme elevations were resolved without further medical intervention.
Earlier this month, Sanofi released results from the GEMINI 1 and 2 phase 3 studies of tolebrutinib that did not meet the primary endpoint of reducing annualized relapse rate (ARR) compared to Aubagio (teriflunomide) in relapsing <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40684403/sanofi-still-bets-on-multiple-sclerosis-med-tolebrutinib-despite-the-investigational-drug-fell-sh" rel="noreferrer noopener">forms of multiple sclerosis</a>.
However, analysis of the key secondary endpoint of pooled 6-month confirmed disability worsening (CDW) data showed a considerable delay in time to onset, which supports the CDP data observed in HERCULES.
In preliminary analysis of the GEMINI 1 and 2 pooled safety data, adverse events observed between the tolebrutinib and Aubagio arms were generally balanced. Liver enzyme elevations were observed in 5.6% of participants receiving tolebrutinib compared with 6.3% of participants receiving Aubagio.
Study results will form the basis for future discussions with global regulatory authorities, with submissions starting in H2 2024.
The PERSEUS phase 3 study in primary progressive MS is ongoing, with study results anticipated in H2 2025.
Price Action: SNY stock is down 0.53% at $57.95 during the premarket session at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40956171/european-drug-agency-supports-novo-nordisks-blockbuster-weight-loss-drug-wegovy-for-obesity-relat" target="_blank" rel="noreferrer noopener">European Drug Agency Supports Novo Nordisk&#8217;s Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure</a>.</li>
</ul>
Image by HJBC via Shutterstock

Biotech

Large Cap

Health Care

General

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows

Jeff Bezos, Oprah Winfrey and Sandra Bullock top the list of celebrities with the highest number of properties in the U.S., each owning seven properties.
An analysis by real estate investment company SoCal homebuyers reveals that celebrity real estate portfolios are reaching new heights amid a growing trend of wealth diversification through property ownership.
Don't Miss:
<ul>
<li>Elon Musk&#8217;s secret mansion in Austin revealed through court filings.<a href="https://www.benzinga.com/money/elon-musk-secret-mansion-austin-nada"> Here&#8217;s how to invest in the city&#8217;s growth before prices go back up.</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>
In terms of value, SoCal homebuyers found that Bezos's portfolio is worth the most at $458.9 million, followed by Jay-Z and Beyoncé, who own five properties worth a total of $315.5 million.
"These <a href="https://www.benzinga.com/real-estate/24/09/40901909/j-los-home-hunt-a-surprising-twist-as-she-considers-property-neighboring-ex-boyfriend-diddy-combs">celebrity portfolios</a> offer valuable lessons for all investors," SoCal homebuyers Co-Founder Doug Van Soest said. "While the scale is impressive, the underlying principles are universal. Diversification, location selection and long-term value appreciation are key, whether you're investing millions or starting with a single property."
Trending: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a>
<h2 class="wp-block-heading">10 Celebrities With Highest Number Of Properties In U.S.</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Rank</td>
<td>Celebrity</td>
<td>Number of properties</td>
</tr>
<tr>
<td>1</td>
<td>Jeff Bezos</td>
<td>7</td>
</tr>
<tr>
<td>1</td>
<td>Oprah Winfrey</td>
<td>7</td>
</tr>
<tr>
<td>1</td>
<td>Sandra Bullock</td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>Leonardo DiCaprio</td>
<td>6</td>
</tr>
<tr>
<td>4</td>
<td>Taylor Swift</td>
<td>6</td>
</tr>
<tr>
<td>6</td>
<td>George Lucas</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>Jay-Z and Beyoncé</td>
<td>5</td>
</tr>
<tr>
<td>6</td>
<td>Kim Kardashian</td>
<td>5</td>
</tr>
<tr>
<td>9</td>
<td>Kylie Jenner</td>
<td>4</td>
</tr>
<tr>
<td>9</td>
<td>Reese Witherspoon</td>
<td>4</td>
</tr>
</tbody>
</table>
</figure>
Source: SoCal homebuyers
Bezos's portfolio includes a $165 million estate in Beverly Hills, California and a $78 million Hawaii resident property, reflecting his penchant for luxury and privacy. The Beverly Hills mansion, formerly owned by media mogul David Geffen, is on nine acres and boasts multiple buildings, a tennis court and a nine-hole golf course.
Trending: Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a>
<a href="https://www.benzinga.com/real-estate/24/07/40001374/from-bill-gates-to-oprah-winfrey-the-most-lavish-celebrity-homes-revealed">Winfrey</a>'s real estate investments range from a sprawling 66-acre estate in Montecito, California, to a ski home in Telluride, Colorado. Her California property, dubbed The Promised Land, features a 23,000-square-foot main house with many luxurious amenities. The Telluride ski house, valued at $14 million, offers mountain views and unique features like a 56-foot-long wine cellar.
Bullock's diverse real estate portfolio includes homes in New Orleans, Southern California and Austin, Texas. Her $2.7 million Victorian home in the Big Easy's Garden District showcases classic architectural details, while her lakefront home in Austin boasts modern design. Her Beverly Hills residence offers privacy in an exclusive gated community.
Trending: Oprah, Madonna and DiCaprio have turned to the alternative asset that is outperforming the S&amp;P 500<a href="https://www.benzinga.com/money/masterworks">. Discover the potential of this market before other investors.</a>
<h2 class="wp-block-heading">10 Celebrities With Highest-Value Property Portfolio In U.S.</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Rank</td>
<td>Celebrity</td>
<td>Total value paid for properties</td>
</tr>
<tr>
<td>1</td>
<td>Jeff Bezos</td>
<td>$458,900,000</td>
</tr>
<tr>
<td>2</td>
<td>Jay-Z and Beyoncé</td>
<td>$315,450,000</td>
</tr>
<tr>
<td>3</td>
<td>George Lucas</td>
<td>$196,100,000</td>
</tr>
<tr>
<td>4</td>
<td>Mark Zuckerberg</td>
<td>$166,000,000</td>
</tr>
<tr>
<td>5</td>
<td>Kim Kardashian</td>
<td>$115,100,000</td>
</tr>
<tr>
<td>6</td>
<td>Taylor Swift</td>
<td>$92,750,000</td>
</tr>
<tr>
<td>7</td>
<td>Ellen DeGeneres</td>
<td>$91,500,000</td>
</tr>
<tr>
<td>8</td>
<td>Oprah Winfrey</td>
<td>$84,415,000</td>
</tr>
<tr>
<td>9</td>
<td>Kylie Jenner</td>
<td>$66,750,000</td>
</tr>
<tr>
<td>10</td>
<td>Madonna</td>
<td>$61,300,000</td>
</tr>
</tbody>
</table>
</figure>
Source: SoCal homebuyers
"In our experience, successful real estate investment is about more than status – it's about making informed decisions based on market trends and potential for growth," Van Soest said. "Even in today's dynamic market, real estate remains a powerful tool for building and preserving wealth when approached strategically."
Read Next:
<ul>
<li>This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a></li>
<li>Commercial real estate has historically outperformed the stock market, and<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> this platform allows individuals to invest in commercial real estate with as little as $5,000 offering a 12% target yield with a bonus 1% return boost today!</a></li>
</ul>

Real Estate

Celebrity Property Portfolios Soar, With Bezos And Oprah Tied For The Top Spot

Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40954941/palantir-expands-maven-smart-system-aiml-capabilities-to-military-services" rel="noreferrer noopener">trading lower in the premarket session on Friday.</a>
The company announced a contract granted by the DEVCOM Army Research Laboratory (ARL) that broadens Maven Smart System access across military branches, including the Army, Air Force, Space Force, Navy, and U.S. Marine Corps.
This firm-fixed price contract totals up to $99.804 million over five years and streamlines the process for services to utilize the existing features of the Maven Smart System. Maven Smart System is part of the National Geospatial-Intelligence Agency&#8217;s Maven AI framework.
&#8220;To stay ahead of our adversaries, we must deliver software advantage at speed and at every level of the Department of Defense,&#8221; said Shannon Clark, Head of Defense Growth, Palantir.&nbsp;
Also Read:<a target="_blank" href="https://www.benzinga.com/news/24/09/40951997/palantir-co-founder-joe-lonsdale-backs-elon-musks-twitter-acquisition-saying-if-he-had-not-bought-it" rel="noreferrer noopener"> Palantir Co-Founder Joe Lonsdale Backs Elon Musk&#8217;s Twitter Acquisition, Saying If He Had Not Bought It Then &#8216;The Entire West Would Be At 10x The Threat&#8217;</a>
Under the latest development, Palantir&#8217;s platform will enhance AI-enabled battlespace awareness and support global integration, force management, logistics, and joint targeting workflows to improve military interoperability and readiness.
&#8220;This contract vehicle will allow every military department to tap into the innovation that the Office of Secretary of Defense and NGA have created through Maven to accelerate their own CJADC2 programs,&#8221; said Akash Jain, President of Palantir USG.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PLTR stock has gained over 149% in the past year. Investors can gain exposure to the stock via&nbsp;REX AI Equity Premium Income ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIPI#NASDAQ">AIPI</a>) and&nbsp;Global X Funds Global X Defense Tech ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHLD#NYSE">SHLD</a>).
Price Action: PLTR shares are trading lower by 2.39% to $35.95 premarket at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40946478/chinas-nio-says-40-of-its-store-managers-are-ex-tesla" target="_blank" rel="noreferrer noopener">China&#8217;s NIO Says 40% Of Its Store Managers Are Ex-Tesla</a></li>
</ul>

Equities

Contracts

AIPI

PLTR

SHLD

Palantir Wins Deal Worth Multi-Million Dollars To Expand Maven Smart System Across US Army, Air Force, Space Force & Navy

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) with a Outperform and raises the price target from $32 to $42.

EWTX

RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $42

NovaBay Pharmaceuticals shares are trading higher after the company announced it reached a definitive deal to sell its Avenova assets for $9.5 million.

B of A Securities analyst Benjamin Haynor maintains Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) with a Buy and lowers the price target from $31 to $19.

VSAT

B of A Securities Maintains Buy on Viasat, Lowers Price Target to $19

<ul>
<li>NVDA</li>
<li>LUNR</li>
<li>MADE</li>
<li>WAY</li>
<li>TSLA</li>
<li>DJT</li>
<li>FDX</li>
<li>LOT</li>
<li>QQQ</li>
<li>AAPL</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

LUNR

MADE

NVDA

Top 10 Trending Stocks On WallStreetBets As Of September 20, 2024 (Via Swaggy Stocks)

On Wednesday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has urged a federal appeals court to overturn a $183 million judgment stemming from accusations of defrauding Medicaid.
The case, initiated in 2014, alleges that Eli Lilly underreported drug prices to Medicaid, resulting in smaller rebates owed to the program.
Last week,&nbsp;Walgreens Boots Alliance&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) agreed to pay $106.8 million to settle allegations that it submitted false claims to government healthcare programs, violating the False Claims Act&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40881893/walgreens-agrees-to-106-8m-settlement-over-alleged-false-billing-claims" rel="noreferrer noopener">and state regulations</a>.
The U.S. pharma giant claims it is being wrongfully held liable despite adhering to its interpretation of Medicaid&#8217;s complex rebate requirements.
The claims also highlight that Eli Lilly failed to disclose price increases billed to distributors, which were not reflected in its Medicaid pricing reports.
Reuters noted that Eli Lilly started reporting price increases after a 2017 rule change, though the company claims it had previously informed regulators about its pricing practices without facing any objections.
In 2022, a U.S. District Judge rejected Eli Lilly&#8217;s motion for summary judgment, ruling that its price statements were misleading and allowing the case to proceed. In May 2023, a jury found Eli Lilly responsible for $61 million in damages, which were tripled to $183 million under the federal False Claims Act.
Most recently, Oak Street Health, a subsidiary of&nbsp;CVS Health&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), agreed to settle for $60 million following allegations that it violated the <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40945496/cvs-subsidiary-oak-street-health-agrees-to-60m-settlement-in-medicare-kickback-violations" rel="noreferrer noopener">False Claims Act</a>.
The&nbsp;<a target="_blank" href="https://www.justice.gov/opa/pr/oak-street-health-agrees-pay-60m-resolve-alleged-false-claims-act-liability-paying-kickbacks" rel="noreferrer noopener">claims</a> involved paying kickbacks to third-party insurance agents to recruit seniors to its primary care clinics, a practice that led to false Medicare submissions.
The case has garnered attention from major business groups, including the U.S. Chamber of Commerce and Pharmaceutical Research and Manufacturers of America (PhRMA). These organizations argue that upholding the judgment would create uncertainty for regulated companies.
Price Action: LLY stock is trading higher by 1.45% to $928.28 premarket at the last check on Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40955083/holiday-opportunity-macys-plans-to-hire-31-500-seasonal-workers" target="_blank" rel="noreferrer noopener">Holiday Opportunity: Macy&#8217;s Plans To Hire 31,500 Seasonal Workers</a>.</li>
</ul>
Photo via Shutterstock

Legal

Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules

Wells Fargo analyst Colin Langan upgrades Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) from Equal-Weight to Overweight and raises the price target from $115 to $122.

Upgrades

Wells Fargo Upgrades Visteon to Overweight, Raises Price Target to $122

RLND

RoyaLand Sees Prelim FY24 Adj. Net Loss $(1.059M)

Biohaven Non-GAAP EPS of -$3.50 misses by $1.80

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biohaven (NYSE:<a href="https://investorplace.com/stock-quotes/bhvn-stock-quote/">BHVN</a>) just reported results for the second quarter of 2024.<ul><li>Biohaven reported earnings per share of -$3.50. This was below the analyst estimate for EPS of -$1.77.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bhvn-stock-earnings-biohaven-for-q2-of-2024/">BHVN Stock Earnings: Biohaven Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BHVN Stock Earnings: Biohaven Misses EPS for Q2 2024

BTIG analyst Thomas Shrader maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) yesterday and set a price target of $59.00. Thomas Sh...

Buy Rating for Biohaven Ltd. Backed by Strong Clinical Data and Strategic Financial Position

Piper Sandler analyst Christopher Raymond assigned a Buy rating to Biohaven Ltd. (BHVN – Research Report) today and set a price target of $66.00. T...

Biohaven Ltd. (BHVN) Gets a Buy from Piper Sandler

Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain

Biohaven Ltd. (BHVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brian Skorney from Rob...

Buy Rating Backed by Biohaven Ltd.'s Promising Clinical Pipeline and Pharmacokinetic Advancements

Jason Gerberry, an analyst from Bank of America Securities, has initiated a new Buy rating on Biohaven Ltd. (BHVN). Jason Gerberry has given his Bu...

Optimistic Outlook: Buy Rating on Biohaven Ltd. for Strategic Approach and Promising R&D Pipeline

BofA starts Biohaven at buy, cites "fast-follower" approach

RBC Capital analyst Leonid Timashev maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) today and set a price target of $59.00. The c...

RBC Capital Sticks to Their Buy Rating for Biohaven Ltd. (BHVN)

Terence Flynn, an analyst from Morgan Stanley, maintained the Buy rating on Biohaven Ltd. (BHVN – Research Report). The associated price target rem...

Buy Rating Affirmed: Biohaven's Robust Drug Pipeline and Strategic Management Decisions Propel Forward Momentum

GLAXF

NBIX

XENE

Earnings

Press Releases

Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments

Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates

Offerings

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Announces Pricing of $230 Million Public Offering of Common Shares

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors

Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day

Management

Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Biohaven

Biohaven (BHVN) Forecast

Biohaven (NYSE:BHVN) Stock, Quote.Headers.trade-ideas